Decheng Capital Global Life Sciences Fund IV, L.P. bought $20M of AARD
owner at Aardvark Therapeutics, Inc.. 1,250,000 shares at an average of $16.00, traded Feb 14, 2025, filed Feb 19, 2025.
Score components
- +12Role10% owner
- +25Trade size$20.0M at market
- +10Relative to holdingsHoldings up 54%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-023409, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 14, 2025 | CConversion Common Stockindirect: By Decheng Capital Global Life Sciences Fund IV, L.P. | +2,333,887 | - | - | 2,333,887 | Feb 19, 2025 |
| Feb 14, 2025 | CConversion Common Stockindirect: By Decheng Capital Global Healthcare Fund (Master), LP | +333,412 | - | - | 333,412 | Feb 19, 2025 |
| Feb 14, 2025 | POpen-market purchase Common Stockindirect: By Decheng Capital Global Life Sciences Fund IV, L.P. | +625,000 | $16.00 | $10M | 2,958,887 | Feb 19, 2025 |
| Feb 14, 2025 | POpen-market purchase Common Stockindirect: By Decheng Capital Global Healthcare Fund (Master), LP | +625,000 | $16.00 | $10M | 958,412 | Feb 19, 2025 |
| Feb 14, 2025 | CConversion Series C Convertible Preferred Stockderivativeindirect: By Decheng Capital Global Life Sciences Fund IV, L.P. | -19,777,363 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | CConversion Series C Convertible Preferred Stockderivativeindirect: By Decheng Capital Global Healthcare Fund (Master), LP | -2,825,337 | $0.00 | $0 | 0 | Feb 19, 2025 |
Related signals
Other insiders at Aardvark Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | Aardvark Therapeutics, Inc. | Nelson Sun See Remarks | $395k 76,754 shares | -68% | |
| 43Moderate | Aardvark Therapeutics, Inc. | Tien-Li Lee Chief Executive Officer | $101k 7,000 shares | +0% | |
| 36Weak | Aardvark Therapeutics, Inc. | Nelson Sun Chief Financial Officer | $43k 3,000 shares | +3% | |
| 51Moderate | Aardvark Therapeutics, Inc. | Tien-Li Lee Chief Executive Officer | $97k 10,000 shares | +1% | |
| 52Moderate | Aardvark Therapeutics, Inc. | Tien-Li Lee Chief Executive Officer | $161k 20,000 shares | +1% | |
| 48Moderate | Aardvark Therapeutics, Inc. | Nelson Sun Chief Financial Officer | $48k 6,000 shares | +6% | |
| 54Moderate | Aardvark Therapeutics, Inc. | Cormorant Asset Management, LP other | $3.0M 187,500 shares | +23% | |
| 51Moderate | Aardvark Therapeutics, Inc. | Nelson Sun Chief Financial Officer | $160k 10,000 shares | +11% | |
| 53Moderate | Aardvark Therapeutics, Inc. | Tien-Li Lee Chief Executive Officer | $265k 16,542 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.